FDA panel supports approval of Glaxo lung drug Anoro

FDA panel supports approval of Glaxo lung drug Anoro

The FDA is not required to follow the advice of its advisory panels but typically does so. Anoro is expected to generate sales of more than $2 billion a year by 2018, according to the average estimate of six analysts polled by Thomson Reuters. A

7
Like
Save

Comments

Write a comment

*